These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 32580246)
1. BRAF mutation, TERT promoter mutation, and HER2 amplification in sporadic or neurofibromatosis-related neurofibromas and malignant peripheral nerve sheath tumors: do these molecules have a signature in malignant transformation? Coskun S; Gamsizkan M; Yilmaz I; Yalcinkaya U; Sungur MA; Buyucek S; Onal B APMIS; 2020 Sep; 128(9):515-522. PubMed ID: 32580246 [TBL] [Abstract][Full Text] [Related]
2. TERT promoter mutations and BRAF mutations are rare in sporadic, and TERT promoter mutations are absent in NF1-related malignant peripheral nerve sheath tumors. Dubbink HJ; Bakels H; Post E; Zwarthoff EC; Verdijk RM J Neurooncol; 2014 Nov; 120(2):267-72. PubMed ID: 25035100 [TBL] [Abstract][Full Text] [Related]
3. Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours. Bottillo I; Ahlquist T; Brekke H; Danielsen SA; van den Berg E; Mertens F; Lothe RA; Dallapiccola B J Pathol; 2009 Apr; 217(5):693-701. PubMed ID: 19142971 [TBL] [Abstract][Full Text] [Related]
4. Expression of the BRAF Shaterian A; Bota D; Leis A Exp Mol Pathol; 2017 Dec; 103(3):276-278. PubMed ID: 29162506 [TBL] [Abstract][Full Text] [Related]
5. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors. Watson KL; Al Sannaa GA; Kivlin CM; Ingram DR; Landers SM; Roland CL; Cormier JN; Hunt KK; Feig BW; Ashleigh Guadagnolo B; Bishop AJ; Wang WL; Slopis JM; McCutcheon IE; Lazar AJ; Torres KE J Neurosurg; 2017 Jan; 126(1):319-329. PubMed ID: 27035165 [TBL] [Abstract][Full Text] [Related]
6. Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma. Mattox AK; Douville C; Silliman N; Ptak J; Dobbyn L; Schaefer J; Popoli M; Blair C; Judge K; Pollard K; Pratilas C; Blakeley J; Rodriguez F; Papadopoulos N; Belzberg A; Bettegowda C Elife; 2022 Mar; 11():. PubMed ID: 35244537 [TBL] [Abstract][Full Text] [Related]
7. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Hirbe AC; Kaushal M; Sharma MK; Dahiya S; Pekmezci M; Perry A; Gutmann DH Cancer; 2017 Apr; 123(7):1194-1201. PubMed ID: 27875628 [TBL] [Abstract][Full Text] [Related]
8. Telomerase activity is a biomarker for high grade malignant peripheral nerve sheath tumors in neurofibromatosis type 1 individuals. Mantripragada KK; Caley M; Stephens P; Jones CJ; Kluwe L; Guha A; Mautner V; Upadhyaya M Genes Chromosomes Cancer; 2008 Mar; 47(3):238-46. PubMed ID: 18069666 [TBL] [Abstract][Full Text] [Related]
10. [Malignant peripheral nerve sheath tumor: a clinicopathological analysis]. Peng W; Gong QX; Fan QH; Liu Y; Song GX; Wei YZ Zhonghua Bing Li Xue Za Zhi; 2023 Sep; 52(9):924-930. PubMed ID: 37670622 [No Abstract] [Full Text] [Related]
11. Chromosomal translocations inactivating CDKN2A support a single path for malignant peripheral nerve sheath tumor initiation. Magallón-Lorenz M; Fernández-Rodríguez J; Terribas E; Creus-Batchiller E; Romagosa C; Estival A; Perez Sidelnikova D; Salvador H; Villanueva A; Blanco I; Carrió M; Lázaro C; Serra E; Gel B Hum Genet; 2021 Aug; 140(8):1241-1252. PubMed ID: 34059954 [TBL] [Abstract][Full Text] [Related]
13. Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas. Pemov A; Hansen NF; Sindiri S; Patidar R; Higham CS; Dombi E; Miettinen MM; Fetsch P; Brems H; Chandrasekharappa SC; Jones K; Zhu B; Wei JS; ; ; Mullikin JC; Wallace MR; Khan J; Legius E; Widemann BC; Stewart DR Neuro Oncol; 2019 Aug; 21(8):981-992. PubMed ID: 30722027 [TBL] [Abstract][Full Text] [Related]
14. SOX9 expression increases with malignant potential in tumors from patients with neurofibromatosis 1 and is not correlated to desert hedgehog. Carbonnelle-Puscian A; Vidal V; Laurendeau I; Valeyrie-Allanore L; Vidaud D; Bièche I; Leroy K; Lantieri L; Wolkenstein P; Schedl A; Ortonne N Hum Pathol; 2011 Mar; 42(3):434-43. PubMed ID: 21193222 [TBL] [Abstract][Full Text] [Related]
15. Atypical neurofibromas reveal distinct epigenetic features with proximity to benign peripheral nerve sheath tumor entities. Kresbach C; Dottermusch M; Eckhardt A; Ristow I; Paplomatas P; Altendorf L; Wefers AK; Bockmayr M; Belakhoua S; Tran I; Pohl L; Neyazi S; Bode H; Farschtschi S; Well L; Friedrich RE; Reuss D; Snuderl M; Hagel C; Mautner VF; Schüller U Neuro Oncol; 2023 Sep; 25(9):1644-1655. PubMed ID: 36866403 [TBL] [Abstract][Full Text] [Related]
16. Frequent MN1 Gene Mutations in Malignant Peripheral Nerve Sheath Tumor. Kinoshita I; Yamada Y; Kohashi K; Yamamoto H; Iwasaki T; Ishihara S; Toda YU; Ito Y; Susuki Y; Kawaguchi K; Ichiki T; Sato Y; Furue M; Nakashima Y; Oda Y Anticancer Res; 2020 Nov; 40(11):6221-6228. PubMed ID: 33109559 [TBL] [Abstract][Full Text] [Related]
17. Other Nerve Sheath Tumors of Brain and Spinal Cord. Petrov M; Sakelarova T; Gerganov V Adv Exp Med Biol; 2023; 1405():363-376. PubMed ID: 37452945 [TBL] [Abstract][Full Text] [Related]